suberoylanilide hydroxamic acid (SAHA), which is called vorinostat, is a histone deacetylase (HDAC) inhibitor approved for cutaneous T-cell lymphoma. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.